Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petri Bono

Showing results (1-10 of 85) with videos related to

Pageof 9
Sort By:
Duodecim; Laaketieteellinen Aikakauskirja|April 6, 2004
[Anti-angiogenic treatment is effective for treating metastatic colorectal cancers]Petri Bono, Heikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2010
[Novel targeted drug therapies in breast cancer]Petri Bono, Heikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|July 27, 2006
[Not Available]Petri Bono, Heikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2004
[Cell surface adhesion molecules and cancer]Petri Bono, Marko Salmi
Cancer|May 27, 2003
Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphomaPetri Bono, Lasse Teerenhovi, Heikki Joensuu
European Journal of Haematology|June 17, 2026
Beyond the Catalogue: Design and Biological Enrichment as the Next Priorities in Higher-Risk MDS Drug DevelopmentAmer M Zeidan, Petri Bono, Joab Williamson
Duodecim; Laaketieteellinen Aikakauskirja|June 18, 2013
[Targeted therapy of a cancer patient is multiprofessional collaboration]Ari Ristimäki, Soili Kytölä, Caj Haglund, et al.
Acta Oncologica (Stockholm, Sweden)|July 29, 2022
C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patientsElisa Kankkunen, Patrick Penttilä, Katriina Peltola, et al.
Acta Oncologica (Stockholm, Sweden)|January 7, 2011
Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinomaPetri Bono, Juhana Rautiola, Tapio Utriainen, et al.
Cancer Immunology Research|November 3, 2023
Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune MicroenvironmentsJenna H Rannikko, Petri Bono, Johanna Hynninen, et al.
Pageof 9

Showing results (1-10 of 85) with videos related to

Sort By:
Pageof 9
Duodecim; Laaketieteellinen Aikakauskirja|April 6, 2004
[Anti-angiogenic treatment is effective for treating metastatic colorectal cancers]Petri Bono, Heikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2010
[Novel targeted drug therapies in breast cancer]Petri Bono, Heikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|July 27, 2006
[Not Available]Petri Bono, Heikki Joensuu
Duodecim; Laaketieteellinen Aikakauskirja|July 6, 2004
[Cell surface adhesion molecules and cancer]Petri Bono, Marko Salmi
Cancer|May 27, 2003
Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphomaPetri Bono, Lasse Teerenhovi, Heikki Joensuu
European Journal of Haematology|June 17, 2026
Beyond the Catalogue: Design and Biological Enrichment as the Next Priorities in Higher-Risk MDS Drug DevelopmentAmer M Zeidan, Petri Bono, Joab Williamson
Duodecim; Laaketieteellinen Aikakauskirja|June 18, 2013
[Targeted therapy of a cancer patient is multiprofessional collaboration]Ari Ristimäki, Soili Kytölä, Caj Haglund, et al.
Acta Oncologica (Stockholm, Sweden)|July 29, 2022
C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patientsElisa Kankkunen, Patrick Penttilä, Katriina Peltola, et al.
Acta Oncologica (Stockholm, Sweden)|January 7, 2011
Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinomaPetri Bono, Juhana Rautiola, Tapio Utriainen, et al.
Cancer Immunology Research|November 3, 2023
Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune MicroenvironmentsJenna H Rannikko, Petri Bono, Johanna Hynninen, et al.
Pageof 9